Capricor Therapeutics (CAPR) Projected to Post Earnings on Tuesday

Posted by George Bondi on Aug 4th, 2026

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) is expected to be posting its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.58) per share and revenue of $2.0830 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). On average, analysts expect Capricor Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded up $0.16 during trading on Tuesday, hitting $4.36. 1,574,736 shares of the company traded hands, compared to its average volume of 1,868,960. The business’s fifty day moving average is $22.51 and its 200 day moving average is $26.64. The firm has a market capitalization of $252.60 million, a price-to-earnings ratio of -1.87 and a beta of 0.54. Capricor Therapeutics has a fifty-two week low of $2.96 and a fifty-two week high of $40.37.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

Negative Sentiment: An FDA panel and agency staff reportedly questioned deramiocel’s effectiveness and the strength of clinical evidence supporting Capricor’s Biologics License Application. The concerns contributed to a reported 64% stock decline and increased uncertainty around the therapy’s approval prospects. StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel
Negative Sentiment: Several law firms announced or promoted a securities class action against Capricor and certain executives. The lawsuits allege that the company made misleading statements about deramiocel and the integrity of clinical data before the stock selloff. The allegations have not been proven in court, but the litigation adds legal, financial and reputational risk. CAPR Stock Drop: Capricor Therapeutics Clinical Data Leads to 64% Stock Drop and Securities Fraud Class Action for Investors
Negative Sentiment: Investors who purchased Capricor securities from December 17, 2025, through July 26, 2026, are being solicited by multiple firms regarding the case. The deadline to seek appointment as lead plaintiff is September 28, 2026, keeping the controversy in focus and potentially increasing future litigation exposure. Kaplan Fox Encourages Capricor Investors to Contact the Firm
Negative Sentiment: JonesTrading downgraded CAPR to “Hold,” reflecting a more cautious view of the company following the regulatory concerns and sharp selloff. Capricor Therapeutics Cut to Hold at JonesTrading

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Maxim Group downgraded shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. B. Riley Financial downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 target price for the company. in a research note on Monday, July 27th. JonesTrading lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. LADENBURG THALM/SH SH cut Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, July 30th. Finally, Oppenheimer reiterated a “market perform” rating on shares of Capricor Therapeutics in a research report on Monday, July 27th. Ten equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $29.15.

View Our Latest Research Report on CAPR

Insider Activity at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer directly owned 11,223 shares of the company’s stock, valued at $340,954.74. The trade was a 68.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders sold 25,000 shares of company stock valued at $759,158. Corporate insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Suvretta Capital Management LLC acquired a new stake in shares of Capricor Therapeutics during the 4th quarter worth about $51,533,000. Tang Capital Management LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth approximately $49,062,000. RA Capital Management L.P. purchased a new stake in shares of Capricor Therapeutics in the 4th quarter valued at about $43,516,000. Darwin Global Management Ltd. purchased a new position in Capricor Therapeutics during the 4th quarter worth $23,168,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth approximately $10,188,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.